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Aim: To assess the effect of intrapleural urokinase, vis-a`-vis simple pleural
drainage, on residual pleural thickening in a series of patients suffering from
loculated tuberculous pleural effusion.
Patients and method: Twenty-nine patients (21 males and 8 females) with loculated
pleural effusion were studied. These patients were randomly allocated to one of two
groups: one group received intrapleural urokinase (n ¼ 12) and the other was
treated by simple drainage with suction (n ¼ 17). The urokinase (125,000 UI) was
administered into the pleural cavity via an intrathoracic tube. This procedure was
repeated every 12 h until the quantity of pleural fluid obtained was less than 50 cm3,
at which point the intrathoracic tube was removed.
Results: In both groups, the biochemical analysis of the pleural fluid was an exudate
and the fluid had a serous appearance. Pleural thickening when the drainage tube
was removed was 8.0973.36mm for the group treated with urokinase, and
14.78717.20mm (P40:05) for the control group. Residual pleural thickening
measured upon completion of medical treatment at 6 months was 1.4570.89mm for
the group treated with urokinase and 7.47710.95mm for the control group
(Po0:05). In the control group, only two patients presented over 10mm of residual
pleural thickening. The mean quantity of fluid drained in the two groups was
1.4877711ml for the patients with urokinase, and 7957519ml for the control group
(Po0:01).
Conclusion: Our study shows that patients with loculated tuberculous pleural
effusion treated with urokinase suffered less from residual pleural thickening, as
measured after six months, than those treated by simple drainage. It is thereforeElsevier Ltd. All rights reserved.
203192.
(E. Cases Viedma).
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E. Cases Viedma et al.2038suggested that the administration of intrapleural urokinase is a safe and effective
treatment for those patients who drain a larger quantity of pleural fluid.
& 2006 Elsevier Ltd. All rights reserved.Introduction
In Spain, up to 23% of all patients with tuberculosis
present tuberculous pleural effusion, and tubercu-
losis is the most frequent cause of pleural effusion
(PE) in patients under 35.1,2 Current treatment for
tuberculosis has a high clinical efficacy rate,3
however, it frequently results in different degrees
of residual pleural thickening. In a series of 45
patients with tuberculous PE, Soler et al.4 found
that 72.6% of them presented pleural thickening, of
which 8.1% were in excess of 15mm, always on the
lower side of the affected hemithorax. This
complication of treatment for tuberculous PE has
been addressed, with no clear benefits, by adding
corticoids both systemically and locally5,6 and with
repeated thoracocentesis7.
Urokinase, for its part, has been successfully
used since the 1960s8 to treat purulent pleurisy and
complicated pleural effusions. Intrapleural fibrino-
lytic agents provide a safe and effective treatment
for loculated PE, reducing morbidity and the need
for surgery.9–13 There are in fact several studies
that assess the use of intrapleural urokinase to
treat encapsulated PE.14–16 However, in spite of the
high frequency of encapsulated tuberculous pleural
effusions, we found only one recent study that
attempted to assess the use of intrapleural uroki-
nase in tuberculous effusions with signs of pleural
loculation.17
The purpose of our randomised prospective study
was to compare the impact on residual pleural
thickening and on the amount of pleural fluid
drained of either administering intrapleural uroki-
nase to, or treating by simple pleural drainage,
patients with loculated tuberculous PE.Patients and procedure
From 1993 to 2003, we studied a total of 97
tuberculous pleural effusions in patients older than
fourteen years old. Of these, 29 (28.3%) corre-
sponded to patients (21 men and 8 women, mean
age of 31) with loculated PE (Table 1). Diagnosis of
loculated PE in these patients had been established
from the findings of chest X-ray examinations,
which showed a lack of layering on decubitus view.
This was subsequently confirmed by the presence ofloculations in the thorax ultrasound examination,
which was performed on all the patients prior to
the insertion of a pleural drainage tube. In those
cases in which a thoracoscopia was needed to
obtain biopsic samples, the presence of pleural
adhesions was confirmed through such direct
thoracoscope examination. The initial PE was sub-
divided into three groups according to radiologic
size: it was defined as small when it occupied less
than 1/3 of the affected hemithorax, as medium
when it occupied less than two-thirds of the
hemithorax, and as large when it occupied up to
2/3 of the hemithorax. Diagnosis of pleural
tuberculosis was established by the presence of
one or more of the following findings: the presence
of necrotising granulomas in the pleural biopsy;
pleural fluid, or biopsy that was positive to Ziehl
staining or Lo¨wenstein–Jensen medium. For 6
months all patients were treated with isoniazid
and rifampicin, together with pyrazinamide during
the first 2 months. In no case were corticoids added
to the treatment.
In the first thoracocentesis, samples of pleural
fluid were taken for biochemistry, cell count,
microbiology and inflammation markers (Table 1).
All patients were fitted with an 18–20 F intercostal
drainage tube which was connected to a graduated
container with a water seal. The patients
were then randomised into two groups: one
of them received intrapleural urokinase (n ¼ 12)
and the other was treated with simple
drainage with suction (n ¼ 17). The urokinase
was prepared in a solution of 125,000 UI of
urokinase with 50ml of saline. This solution was
administered into the pleural cavity via an in-
trathoracic tube. The tube was subsequently sealed
for two hours and then connected to suction of up
to 25 cm of H2O. This procedure was repeated
every 12 h until the amount of pleural fluid
extracted was less than 50 cm3, at which point
the intrathoracic tube was removed. The average
dosage administered to each patient was 3.572
(range 2–8).
The main variable of interest to our study was
pleural thickening, as assessed at the end of pleural
drainage and after completion of treatment.
Pleural thickening was measured on the lower side
of a posteroanterior chest X-ray and recorded in
millimetres. Other variables were also evaluated,
including the quantity of drained fluid, the duration
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Table 1 Patient characteristics and analysis of pleural fluid.
Patients With urokinase (n ¼ 12) Control (n ¼ 17) P
Patient characteristics
Number (males/females) 12 (8/4) 17 (13/4)
Mean age (years) 29 32 NS
Range 22–39 15–51
Radiologic characteristics
Small 5 4 NS
Moderate 3 6 NS
Large 4 7 NS
Analysis of pleural fluid
PH 7.2370.07 7.2470.07 NS
Glucose (mg/dl) 63717 70724 NS
Proteins (gr/dl) 5.4270.5 4.9270.71 o0.02
LDH (U/l) 10817436 12607616 NS
LDH p/s 4.0772.64 3.5072.62 NS
ADA (U/l) 68.83715.02 82.63723.46 NS
INF-g (pg/ml) 395573073 534473711 NS
Total cells ( 103/ml) 3.473.9 2.572.5 NS
Lymphocytes (%) 89710 88713 NS
Values expressed as mean7SD.
ADA, adenosine deaminase; INF-g, interferon g; LDH, lactic acid dehydrogenase; NS, not significant.
A study of loculated tuberculous pleural effusions 2039of the drainage process, and the length of
hospitalisation.
The results below are recorded as the mean7
standard deviation from the mean. A Student’s
t-test and a w2 test were conducted to determine
the statistical significance of the differences and
relationships between variables observed between
the two groups, respectively. The level of statis-
tical significance was set at Po0:05.Results
The quantity of PE as determined by the initial
X-ray findings was similar in the two groups (Table 1).
Table 1 also shows the characteristics of the pleural
fluid, including the total number of leukocytes, the
percentage of lymphocytes, the levels of glucose,
proteins, lactic acid dehydrogenase (LDH) and
inflammation markers resulting from the first
thoracocentesis. No significant differences were
found between the biochemical parameters of the
two groups, except for pleural proteins. Neither
were differences found between the cell count and
percentage of lymphocytes, or the inflammation
markers, adenosine deaminase (ADA) and interfer-
on g. In both groups, the biochemical analysis of the
pleural fluid was an exudate and the fluid had aserous appearance. Glucose in the pleural fluid was
significantly lower than blood glucose (group
treated with urokinase: 63717 and 101718,
Po0:05; control group: 70724 and 9979,
Po0:05), and no difference was found between
glucose in pleural fluid in the two groups. The pH of
the pleural fluid was low in the two groups
(7.2370.07 and 7.2470.08, respectively,
P4 0:05). None of the patients presented local
complications at the point of insertion of the
intrathoracic tube, nor were systemic complica-
tions observed during drainage.
Pleural thickening when the drainage tube was
removed was 8.0973.36mm for the group treated
with urokinase and 14.78717.20mm for the con-
trol group (P40:05). Residual pleural thickening
measured upon completion of the medical treat-
ment at six months was 1.4570.89mm for the
group treated with urokinase and 7.47710.95mm
for the control group (Po0:05). Only two patients
in the control group presented over 10mm of
pleural thickening. The mean quantity of fluid
drained was 1.4877711 cm3 for the patients
treated with urokinase and 7957519ml for the
control group (Po0:01). Table 2 compares the
hospitalisation times for the two groups, the time
between admission and drainage placement, and
the duration of drainage. No significant differences
were found regarding any of these parameters.
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Table 2 Initial pleural thickening (PT) on removal of drainage tube and final PT (after 6 months).
Parameters (range) With urokinase (n ¼ 12) Control (n ¼ 17) P
Initial PT (mm) 8.0973.36 14.78717.20 NS
Final PT (mm) 1.4570.89 7.47710.95 o0.05
Drainage quantity (ml) 14877711 (150–3000) 7957519 (150–1500) o0.01
Duration of hospitalitation (days) 14.7274.22 (7–20) 16.8576.24 (7–26) NS
Duration of fever after drainage placement (days) 3.6372.06 (1–6) 4.5072.88 (1–8) NS
Duration of pleural drainage (days) 2.6671.72 (2–8) 2.4270.78 (2–4) NS
Pleural drainage and clinical parameters. Values expressed as mean7SD (range).
NS, not significant; PT, pleural thickening.
E. Cases Viedma et al.2040No patient required surgery and there were no
fatalities. Urokinase was tolerated well by all
twelve patients and no bleeding was observed in
these patients.Discussion
Our results show that the treatment of loculated
tuberculous pleural effusion with drainage plus
urokinase leads to less residual pleural thickening
than treatment with simple pleural drainage.
Residual pleural thickening is a relatively frequent
complication in cases of tuberculous PE. In order to
reduce the severe inflammatory reaction that
patients with tubercolous PE experience, past
studies have administered corticoids. Such a treat-
ment, however, has failed to reduce pleural
thickening in the affected patients.18–20 Corticoids
were not used in our study, and all the patients
received tuberculosis medical treatment in addi-
tion to pleural drainage. Urokinase has also been
used to try to reduce pleural thickening in cases of
complicated parapneumonic effusions. Urokinase
activates plasminogen, converting it into plasmin, a
non-specific proteolytic enzyme. Plasmin is capable
of degrading fibrinogen and fibrin clots, thus
reducing pleural walls and facilitating drainage of
the pleural cavity. We have only found one study
conducted by Ding et al.21 on a series of tubercu-
lous pleural effusions in which urokinase was added
to prevent the development of pleural thickening.
Ding et al.’s study is however different from ours in
that, in theirs, urokinase was used in cases that did
not show pleural loculation. Recently, Kwak et al.17
conducted a similar study to ours, in which they
treated patients with loculated PE with urokinase.
The results of Kwak et al.’s study were similar to
ours, albeit that their monitoring period was
shorter than ours.Another variable that is usually assessed in
studies which use intrapleural fibrinolytic agents
is the amount of fluid that can be drained. Our
findings show that those patients with tuberculous
PE who were treated with urokinase drained more
pleural fluid than those in the control group. This
result coincides with the findings in Bouros et al.9 in
which the amount of fluid drained in non-tubercu-
lous pleural effusions was significantly greater in
the urokinase group than in the control group. Both
Kwak et al. and Bouros et al. studies on tuberculous
pleural effusion coincide in this respect. Since in
our study the quantity of fluid drained was greater
in the group treated with urokinase, we believe this
was due to the effect of the urokinase, which
produced lysis of the pleural adhesions. Lysis
contributed to diminishing pleural thickening,
whereas according to Bouros et al.12 rupture of
the adhesions would not diminish residual pleural
thickening. It is also possible that the increase in
the amount of drained fluid in the group treated
with urokinase was due to the amount of saline
fluid administered with the urokinase. However,
since the latter was significantly lower than the
amount of fluid drained, we believe that it had no
consequence on the total volume of drained fluid
that was obtained.
In most cases, we conducted a thorax ultrasound
examination prior to insertion of the drainage tube
in order to locate the best drainage point. In no
case was it necessary to use a CT scan or multiple
catheterisation. With regards to catheter size, we
used a medium grade size catheter in both groups,
which allowed for the drainage of dead tissue that
is so common in this type of complicated pleural
effusion. No differences were found between the
groups as regards either the patients’ character-
istics, the quantity of PE or the analysis of their
initial pleural fluid. Both groups presented a similar
degree of pleural inflammation based on LDH values
and inflammation markers, as well as similarly
low glucose and pH values.22 In both groups, the
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pleural thickening as a complication of these
pleural effusions.4 The doses of urokinase adminis-
tered was 250,000 UI every 24 h. This dose, which is
retained in the pleural cavity for 2 or 3 h before
connecting the drainage, is that most frequently
used in the bibliography consulted.10,12,15 Drainage
time was similar in both groups, as was the time
that it took for the fever to disappear after starting
pleural drainage, irrespective of urokinase. Drai-
nage time, therefore, does not appear to affect
residual pleural thickening which, as we have
reported, was significantly lower in the group
treated with urokinase. However, the time taken
to inject the fibrinolytic agent does appear to have
an impact on residual pleural thickening; the
sooner treatment is started, the smaller the
collagen deposits, which in turn favours disappear-
ance of the PE.12 In our study, there was no time
difference between the groups vis-a`-vis either
urokinase administration or pleural drainage.
Bouros et al. found a reduction in the length of
hospitalisation and the number of days of pleural
drainage required in patients with purulent pleurisy
treated with urokinase.12 We found no such
difference, although the length of hospitalisation
in days for the group treated with urokinase in our
study was similar to that found by these authors.
Other studies that have used streptokinase have
found no differences between the treatment and
the control groups as regards these parameters
compared.23,24 We believe that this could be due to
factors such as early start of treatment, the dose
and type of fibrinolytic agent used, or the size of
the drainage tube.
In our opinion, the use of urokinase is justified in
those patients who show loculation of the pleural
cavity and when factors predicting that residual
pleural thickening will be over 10mm can be
identified. Indeed, we found two patients in the
control group with over 10mm of pleural thickening
and none in the group treated with urokinase. Our
belief is based on: firstly, that pleural thickening is
reduced between removal of the drainage tube and
completion of treatment (as described by De Pablo
et al.25 who found a reduction in pleural thickening
and even normalisation after a one-year period;
and secondly, that functional sequelae in patients
with tuberculous residual pleural thickening of up
to 2mm are irrelevant (although in patients with
pleural thickening over 10mm there appears to be
a reduction in pulmonary volume26).
To conclude, our study showed that patients with
loculated tuberculous pleural effusion treated with
urokinase had less residual pleural thickening, as
measured after 6 months, than those treated withsimple drainage. Administration of intrapleural
urokinase is therefore a safe treatment for those
patients with loculated tuberculous PE. Although
functional sequelae in this type of PE are both
common and irrelevant, we believe that adminis-
tration of urokinase in patients with loculated
effusion is nevertheless to be recommended.Acknowledgments
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